How to Invest in GLP-1 and obesity drugs
Short answer
You can invest in GLP-1 and obesity drugs by buying the individual stocks that fit the thesis (LLY, NVO, AMGN, VKTX, PFE), holding a broad healthcare ETF proxy like XLV, or building a focused GLP-1 basket in Walnut. The theme covers the makers of GLP-1 medicines for diabetes and obesity, the established leaders generating large revenue today, and the next-wave developers chasing improved drugs. Demand has far outstripped supply, the market is large and growing, but it is concentrated in two dominant players, with patent timelines and clinical results as the key swing factors.
How do GLP-1 drugs work?
GLP-1 drugs mimic a natural gut hormone (glucagon-like peptide-1) that the body releases after eating. By activating the same receptors, these medicines slow digestion, reduce appetite, and help regulate blood sugar, which is why they were first approved for type 2 diabetes and then for weight loss. That mechanism, suppressing appetite and improving metabolic control, is the foundation of the GLP-1 and obesity drugs theme and the reason demand has been so strong.
The companies in the GLP-1 and obesity drugs theme are racing to make these medicines more effective and easier to take. LLY (Eli Lilly) and NVO (Novo Nordisk) market the leading injectable drugs today, while the next wave focuses on oral formulations, longer dosing intervals, and combinations that add muscle preservation or greater weight loss. VKTX (Viking Therapeutics) is a closely watched clinical-stage developer, and AMGN and PFE are large pharma companies pursuing their own GLP-1 and related obesity programs.
Why is the GLP-1 market so large?
The GLP-1 and obesity drugs market is large because the addressable population is enormous. Obesity and type 2 diabetes affect hundreds of millions of people worldwide, and GLP-1 medicines have shown meaningful weight loss and metabolic benefits, plus emerging evidence of cardiovascular and other health benefits that could expand approved uses further. Demand has repeatedly outstripped supply, with the leaders racing to expand manufacturing capacity, which is a defining feature of the GLP-1 and obesity drugs theme.
This scale is why the theme commands so much investor attention. LLY and NVO have generated large and fast-growing revenue from their GLP-1 franchises, reshaping their company profiles. The growth potential, if these drugs reach more patients and more indications, is what draws challengers like AMGN, PFE, and VKTX into the GLP-1 and obesity drugs theme despite the dominance of the two incumbents. The size of the prize sustains a crowded development race.
What are the key risks in the GLP-1 theme?
The GLP-1 and obesity drugs theme carries several specific risks. The first is concentration: two companies, LLY and NVO, dominate the current market, so the theme is heavily exposed to their pricing, manufacturing, and clinical execution. The second is patents and competition: blockbuster drugs eventually face patent expiration and a wave of competing or cheaper alternatives, which can erode the franchises over time. The third is clinical and regulatory risk, especially for the challengers.
For pipeline names in the GLP-1 and obesity drugs theme, like VKTX, the swing factor is binary clinical-trial results: a strong trial can re-rate the stock sharply, while a setback can be severe, since the company's value rests on drugs not yet approved. Pricing pressure and insurance coverage decisions also matter across the theme, because access at scale depends on payers. So while the GLP-1 and obesity drugs theme has powerful demand tailwinds, the equity risks are concentrated, patent-sensitive, and event-driven.
What gets a stock into the GLP-1 and obesity drugs theme?
Revenue or pipeline exposure to GLP-1 and obesity medicines: marketed GLP-1 drug franchises, large pharma with significant obesity programs, and clinical-stage developers of next-generation metabolic drugs.
What stocks are in the GLP-1 and obesity drugs theme?
Every public name that fits the GLP-1 and obesity drugs thesis, with the rationale for inclusion. Click any ticker for the full stock guide. The basket above starts equal-weighted; you set your own target weights inside Walnut.
Eli Lilly markets a leading GLP-1 franchise for diabetes and obesity and has a deep next-generation metabolic pipeline.
Novo Nordisk is the other dominant GLP-1 leader, with marketed obesity and diabetes drugs and large manufacturing investment.
Amgen is a large biotech developing its own obesity and metabolic programs aiming at the next wave of treatments.
Viking Therapeutics is a closely watched clinical-stage developer of next-generation metabolic drugs; value rests on trial results.
Pfizer is a large diversified pharma pursuing oral GLP-1 and obesity programs to compete in the growing market.
How to invest in GLP-1 and obesity drugs
There are a few ways to get exposure to the GLP-1 and obesity drugs theme, and Walnut is not an investment adviser, so this is descriptive. The most concentrated path is buying individual stocks that fit the thesis. The two dominant leaders, LLY and NVO, give exposure to the established, revenue-generating franchises, while AMGN and PFE add large diversified pharma chasing the next wave, and VKTX is a clinical-stage developer whose value depends on trial outcomes. Choosing single names lets you set how much sits in the proven leaders versus the speculative pipeline, which matters in the GLP-1 and obesity drugs theme because those groups carry very different risk. The passive route is the broad healthcare ETF XLV, which holds LLY and the big pharma names but dilutes the GLP-1 exposure across the entire sector, so it is far from a pure-play vehicle. There is no dedicated obesity-drug ETF in Walnut's valid proxy set as of early 2026.
The alternative is building a dedicated GLP-1 basket in Walnut. You describe the thesis to Walnut's AI assistant, for instance GLP-1 and obesity drugs spanning the market leaders and the next-wave developers, and the assistant proposes constituents and starting weights drawn from names like LLY, NVO, AMGN, PFE, and VKTX, with the rationale for each. You can deliberately balance the dominant leaders against the more speculative pipeline names, review and adjust every weight, and fund the basket through your own connected broker. You approve every order before it is placed; Walnut never trades for you. The GLP-1 basket then tracks as a single performance line you can compare against XLV.
Which ETFs cover GLP-1 and obesity drugs?
If you want the theme as a single ticker rather than as a basket, these are the ETFs people most commonly use. Each has trade-offs (concentration, expense ratio, sector overlap) covered in the individual ETF guides.
The bottom line on GLP-1 and obesity drugs
GLP-1 and obesity drugs is a large, fast-growing pharmaceutical market dominated by two players (LLY, NVO), with established diversified pharma (AMGN, PFE) and clinical-stage challengers (VKTX) competing for the next wave. It fits a portfolio as a healthcare satellite tilt, and a focused basket lets you balance the two leaders against the more speculative pipeline names more cleanly than XLV, where GLP-1 exposure is buried inside the broad healthcare sector.
FAQ
What is the GLP-1 and obesity drugs theme?
+
GLP-1 and obesity drugs groups makers of GLP-1 medicines for diabetes and weight loss. It includes the two dominant leaders (LLY, NVO) generating large revenue today, large diversified pharma chasing the next wave (AMGN, PFE), and clinical-stage developers (VKTX). The market is large and fast-growing with demand outstripping supply, but concentrated in two players, with patents and clinical results as key swing factors.
What are the best GLP-1 and obesity drug stocks?
+
Walnut isn't an investment adviser. The names most tied to the theme as of early 2026 are LLY and NVO as the dominant leaders, AMGN and PFE as large pharma pursuing the next wave, and VKTX as a clinical-stage developer. The leaders generate substantial revenue today; the pipeline names are more speculative, so the mix you choose drives the basket's risk profile.
Is there a GLP-1 or obesity drug ETF?
+
There's no dedicated obesity-drug ETF in Walnut's valid proxy set as of early 2026, though specialized ones exist in the broader market. The closest valid proxy is XLV, the broad healthcare sector ETF, which holds LLY and big pharma but dilutes GLP-1 exposure across the whole sector. A focused Walnut basket isolates the GLP-1 names far more cleanly.
How do I invest in GLP-1 and obesity drugs?
+
Three approaches. (1) Buy XLV for diluted healthcare-sector exposure that includes the leaders. (2) Buy the names directly, choosing your mix of proven leaders (LLY, NVO) and pipeline names (AMGN, PFE, VKTX). (3) Build a Walnut basket balancing the dominant leaders against speculative developers, with weights you set. Walnut isn't an investment adviser; you approve every order before it's placed.
How do GLP-1 drugs actually work?
+
GLP-1 drugs mimic a natural gut hormone the body releases after eating. By activating the same receptors, they slow digestion, reduce appetite, and help regulate blood sugar, which is why they were approved first for type 2 diabetes and then for weight loss. That appetite-suppressing, metabolic mechanism is the foundation of the GLP-1 and obesity drugs theme and the reason demand has been so strong.
What's the difference between Eli Lilly and Novo Nordisk?
+
Eli Lilly (LLY) and Novo Nordisk (NVO) are the two dominant GLP-1 makers, each marketing leading injectable drugs for diabetes and obesity and each investing heavily in manufacturing. They compete head-to-head on efficacy, dosing, and next-generation pipelines. Within the GLP-1 and obesity drugs theme they're the two anchors, and the theme's concentration in these two names is one of its defining risks.
Why is Viking Therapeutics (VKTX) a high-risk GLP-1 stock?
+
Walnut isn't an investment adviser. Factually, Viking Therapeutics (VKTX) is a clinical-stage developer whose value rests on drugs not yet approved, so its stock swings sharply on binary trial results: strong data can re-rate it up, a setback can be severe. Within the GLP-1 and obesity drugs theme it represents the speculative pipeline end, distinct from the revenue-generating leaders. Size it accordingly.
Why is the GLP-1 market so large?
+
The addressable population is enormous: obesity and type 2 diabetes affect hundreds of millions worldwide. GLP-1 medicines show meaningful weight loss and metabolic benefits, plus emerging cardiovascular and other benefits that could expand approved uses. Demand has repeatedly outstripped supply, pushing the leaders to expand manufacturing. That scale is why the GLP-1 and obesity drugs theme draws so much investor attention and so many challengers.
What are the risks of a GLP-1 basket?
+
Three. (1) Concentration: LLY and NVO dominate, so the theme is heavily exposed to two companies' pricing, manufacturing, and execution. (2) Patents and competition: blockbuster drugs eventually face expiration and cheaper alternatives. (3) Clinical and pricing risk: pipeline names like VKTX swing on trial results, and payer coverage decisions affect access across the theme. Walnut isn't an investment adviser.
Can I build a GLP-1 basket in Walnut?
+
Yes. Tell Walnut's AI assistant something like 'GLP-1 and obesity drugs across the leaders and next-wave developers' and it proposes a basket spanning LLY, NVO, AMGN, PFE, and VKTX with weights you set. You can balance the dominant leaders against speculative pipeline names, review the rationale, and fund through your broker. The basket tracks as one performance line you can compare to XLV.
Build the GLP-1 and obesity drugs basket in Walnut
Walnut's AI assistant takes the thesis above, proposes 5 to 6 constituents with target weights, and lets you fund the basket through your existing broker. You approve every order; we never trade on your behalf.
Other themes
- AI infrastructure. Picks and shovels of the AI buildout: GPUs, networking, foundries, and the software platforms training the largest models.
- Data center power and cooling. The grid, switchgear, liquid cooling, and electrical contracting that AI data centers can't run without.
- Semiconductors. The full chip stack: designers, foundries, equipment makers, materials suppliers, and packaging specialists.
- Defense and modernization. Software, sensors, and specialty materials at the center of US and allied defense buildouts.
- Critical materials. Rare earths, specialty metals, and strategic materials at the center of supply chain reshoring.
Walnut is informational, not investment advice. Theme membership is descriptive, not prescriptive; nothing on this page should be read as a recommendation. Always verify current financials and your own circumstances before investing.